Photo protocol When to take photos: Day 1 before starting Every 2 weeks (same day, same time) Always in morning, before eating, after bathroom How to take photos: Same lighting every time (natural window light ideal) Same location, same distance from camera Same poses: front relaxed, front flexed, side relaxed, side flexed, back Wear minimal clothing (underwear works) No filters, no editing Common mistakes: Inconsistent lighting (biggest factor in bad comparisons) Different times of day (water retention varies) Flexing in "after" but not "before" Cherry-picking best angles Measurements matter more than scale Track these every 2 weeks: Body weight (same time, same conditions) Waist circumference (at navel) Chest, arms, thighs (if building muscle) Body fat percentage (calipers or DEXA) Photos + measurements + strength progression = complete picture
We haven't really given a solution around that, but it's like reducing environmental toxins as much as possible
Key Semaglutide Market Insights Summary: Regional Highlights: North America in the semaglutide market is anticipated to secure a 50.8% share by 2035, with regional expansion being stimulated by strong direct-to-consumer commercialization, favorable reimbursement expansions, and high prevalence of diabetes and obesity Asia Pacific is poised to emerge as the fastest-growing regional market throughout 2026-2035, with momentum accelerated by expanding healthcare expenditure, rising GLP-1 receptor acceptance, increasing obesity and diabetes prevalence, and improved accessibility to generic and branded formulations Segment Insights: The injection segment in the semaglutide market is projected to account for an 81.9% share by 2035, with segment progression being reinforced by delivering medications directly into the bloodstream, tissues, or muscles for enabling increased onset of action, treating uncooperative or unconscious patients, and bypassing the digestive tract to combat drug degradation The type 2 diabetes sub-segment is expected to capture the second-largest share during 2026-2035, with growth being energized by its recognition as a chronic condition wherein the body resists insulin or fails to produce sufficient insulin leading to high blood sugar levels Key Growth Trends: Prevalence of dietary shifts Expansion in wellness programs Major Challenges: Ethical concerns for off-label prescribing and cosmetic utilization Protein stability and cold chain requirements Key Players: Novo Nordisk (Denmark), Eli Lilly and Company (U.S.), Pfizer Inc
L.PrachtE.BorensteinA
The most popular medication is not automatically the right medication
Researchers investigate these components in preclinical and in vitro work related to extracellular matrix biology, cell migration signaling, and tissue model recovery
.jpg?v=1738588738755)
